Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Cystic Fibrosis
Interventions: Candy Glucose Tolerance Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 10 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Huntington Disease
Interventions: SPK-10001, Placebo Surgery Control; Genetic · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 5
States / cities: Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more

Conditions: Sickle Cell Disease, Sickle Cell Trait
Interventions: CHOICES, eBook; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 45 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease
Interventions: enzyme analysis; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: thioureidobutyronitrile; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fanconi Anemia
Interventions: Cyclophosphamide, Fludarabine, Total body irradiation (TBI); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Tourette Syndrome
Interventions: Medtronic Percept Neurostimulator; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: MPNST, NF1, Sarcoma
Interventions: Selumetinib + ZEN-3694 ± Durvalumab; Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atopic Dermatitis
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more

Conditions: Dysphagia of Newborn
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Day to 3 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Candidiasis
Interventions: fluconazole, placebo; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: 2 Days to 5 Days
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 33
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more

Conditions: Chronic Granulomatous Disease
Interventions: Nexell Isolex with T-cell Depletion, Baxter isolex 300i; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatitis, Atopic, Pruritus
Interventions: ASN008, ASN008 Matching Vehicle; Drug · Other
Lead sponsor: Formation Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more

Conditions: Cancer
Interventions: acyclovir, acyclovir sodium, valacyclovir; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 6
States / cities: Duarte, California • Stanford, California • Omaha, Nebraska + 3 more

Conditions: Fragile X Syndrome
Interventions: BPN14770/ zatolmilast, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Sacramento, California + 14 more

Conditions: Craniosynostoses
Interventions: MRI,DTI, functional MRI; Diagnostic Test
Lead sponsor: University of Arkansas; Other
Eligibility: Up to 4 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more

Conditions: Vulvar Lichen Sclerosus
Interventions: The CO2RE® System; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont

Conditions: Fragile X Syndrome, Genetic Diseases
Interventions: Lovastatin, Placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Pompe Disease (Late-onset)
Interventions: AT2221, ATB200; Drug · Biological
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Little Rock, Arkansas • Irvine, California • Gainesville, Florida + 14 more

Conditions: Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma, Refractory Neurofibromatosis Type 1, Refractory Visual Pathway Glioma
Interventions: Biospecimen Collection, Selumetinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more

Conditions: Single Ventricle Defect
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Months to 10 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Transplant
Interventions: Arm 1 Everolimus/Reduced dose tacrolimus; Drug
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 7 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more

Search by objective public record fields.

Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

CHOICES3: Sickle Cell Disease Parenting CHOICES

Identification of Undiagnosed Lysosomal Acid Lipase Deficiency

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Tourette Deep Brain Stimulation (DBS) Target Detection & Suppression

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Evaluating Dysphagia in Neonates With CHD

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

Neurodevelopmental Outcomes in Craniosynostosis Repair

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

The CO2RE® System for Vulvar Lichen Sclerosus

Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A